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Abstract  
ErbB2 over-expression is detected in approximately 25% of invasive breast cancers and is strongly 
associated with poor patient survival. We have previously demonstrated that p130Cas adaptor is a 
crucial mediator of ErbB2 transformation. Here, we analyzed the molecular mechanisms through 
which p130Cas controls ErbB2-dependent invasion in three-dimensional cultures of mammary 
epithelial cells. Concomitant p130Cas over-expression and ErbB2 activation enhance PI3K/Akt and 
Erk1/2 MAPK signalling pathways and promote invasion of mammary acini. By using 
pharmacological inhibitors, we demonstrate that both signalling cascades are required for the 
invasive behaviour of p130Cas over-expressing and ErbB2 activated acini. Erk1/2 MAPK and 
PI3K/Akt signalling triggers invasion through distinct downstream effectors involving 
mTOR/p70S6K and Rac1 activation, respectively. Moreover, in silico analyses indicate that 
p130Cas expression in ErbB2 positive human breast cancers significantly correlates with higher risk 
to develop distant metastasis, thus underlying the value of the p130Cas/ErbB2 synergism in 
regulating breast cancer invasion. In conclusion, high levels of p130Cas favour progression of 
ErbB2 transformed cells towards an invasive phenotype. 
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Introduction  
The ErbB2 oncogene (also known as HER2) belongs to the epidermal growth factor-receptor family 
and its over-expression and activation have been detected in a large subset of mammary cancers 
(Hynes and Lane, 2005). Amplification or over-expression of the ErbB2 gene has been detected in 
many cancers, including human breast, lung and gastric cancers and is associated with increased 
tumor grade and shorter overall survival rates (Allgayer et al., 2000; Sharma and Settleman, 2009; 
Slamon et al., 1989). ErbB2 activation is associated with an increase of its tyrosine phosphorylation 
and results in the phosphorylation of a host of downstream molecules, which in turn activate a 
variety of signalling cascades, including phosphatidylinositol-3 kinase (PI3K)/Akt, Src kinase, 
phospholipase C gamma and the RAS/mitogen activated protein kinase cascade (Baselga and 
Swain, 2009; Hynes and Lane, 2005; Hynes and MacDonald, 2009; Neve et al., 2002; Yarden and 
Sliwkowski, 2001). 
p130Cas was originally identified as a tyrosine phosphorylated protein upon transformation by v- 
and v-Crk oncogenes and for its ability to associate with Crk (Matsuda et al., 1990; Reynolds et al., 
1989). p130Cas is a multifunctional adaptor protein required for embryonic development  (Honda et 
al., 1998) and is characterized by structural motifs that enable interactions with a variety of 
signaling molecules. These multi-protein complexes sense and integrate signalling originating from 
several receptor systems (Bouton et al., 2001; Defilippi et al., 2006; O'Neill et al., 2000).  
p130Cas functions as a molecular scaffold within focal adhesion complexes, and is readily 
phosphorylated by focal adhesion kinase (FAK) and c-Src (Mitra and Schlaepfer, 2006). For its 
inclusion in focal adhesion complexes, p130Cas has also been proposed to play a critical role in 
mediating cell migration and invasion. Indeed, fibroblasts derived from p130Cas-deficient embryos 
exhibit drastically altered cytoskeletal architectures (Honda et al., 1998) and after transformation 
with c-Src become significantly more invasive when engineered to simultaneously over-express 
p130Cas (Brabeck 2004). In addition, p130Cas association with Crk constitutes a molecular switch 
for cell motility by recruiting DOCK180 to integrin-containing adhesion complexes (Klemke et al., 
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1998). Moreover, c-Src-mediated p130Cas phosphorylation and the assembly of a p130Cas–Crk–
DOCK180 scaffold drive cell migration and responses to mechanical stress (Mitra and Schlaepfer, 
2006; Stupack et al., 2000) 
Recent data support a role for p130Cas in the acquirement of resistance to breast cancer therapy. It 
has been shown that patients with primary breast tumors expressing high levels of p130Cas (also 
known as BCAR-1) experience a more rapid disease recurrence and have a greater risk of resistance 
to tamoxifen therapy (van der Flier et al., 2000). Moreover, over-expression of p130Cas/BCAR1 
can confer breast cancer resistance to adriamycin (Ta et al., 2008).  
We have previously shown that double transgenic mice originated by crossing MMTV-p130Cas and 
MMTV-NeuT mice, that express the oncogenic form of the rat neu gene, homologous to human 
ErbB2 (Muller et al., 1988; Nanni et al., 2000), showed an accelerated onset of mammary tumour 
formation (Cabodi et al., 2006). In addition, the analysis of human breast samples revealed that 
tumours over-expressing both p130Cas and ErbB2 are characterised by an elevated proliferation 
index (Cabodi et al., 2006). We have also recently shown that p130Cas is an essential transducer 
element in ErbB2 transformation, demonstrating that p130Cas is necessary for ErbB2-dependent 
foci formation, anchorage-independent growth, in vivo tumour growth and lung colonisation 
(Cabodi etal., 2010).  
The human mammary cells MCF10A.B2 that express a chimeric form of ErbB2, which can 
homodimerize in the presence of the synthetic ligand AP1510 (Muthuswamy et al., 2001), are a 
suitable in vitro model for the study the ErbB2-dependent transformation in three-dimensional (3D) 
matrix instead of the classical monolayer culture. Here, we uncover the molecular mechanisms
 
for 
p130Cas-dependent invasiveness of ErbB2 transformed cells showing that p130Cas drives invasion 
of ErbB2-transformed mammary acinar structures by enhancing activation of mTOR/p70S6K and 
Rac1. 
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Material and Methods 
Antibodies and reagents  
Mouse monoclonal antibodies to p130Cas and beta-1 integrin and rabbit polyclonal antibodies to 
fibronectin were produced at the MBC, University of Torino. Phospho Src (Y416), phospho Erk1/2 
(T202/T204), phospho Akt (S473), phospho S6Rp (S235/236), S6Rp, Erk1/2 MAPK, Akt, phospho 
p70S6K T389 and T421/S424, p70S6K antibodies were obtained from Cell Signaling (Beverly, 
MA), Rac1 antibody was from Millipore (Billerica, MA, USA). c-Src antibody was from Santa 
Cruz (Palo Alto, CA, USA). Rac inhibitor (NSC23766) was from Calbiochem (Merck KGaA, 
Darmstadt, Germany), MAPKK inhibitor (PD98059), Src inhibitor (SU6656) and PI3K inhibitor 
(LY294002) from Sigma (St. Louis, MO, USA), Rapamycin was from Cell signalling. Matrigel and 
collagen I were purchased from BD Trasduction Laboratories (Franklin Lakes, NY). Secondary 
antibodies conjugated with peroxidase were purchased from GE Healthcare. Alexa Fluor 633 
phalloidin and Alexa Fluor Dye secondary antibodies were from Invitrogen (Carlsbad, CA, USA). 
Cell cultures 
MCF10A.B2 engineered cells were kindly provided by Dr. Muthuswamy (Cold Spring Harbor 
Laboratory), (Muthuswamy et al., 2001). MCF10A.B2 cells were maintained in DMEM/F12 
(Gibco, BRL) supplemented with 5% horse serum, 20 ng/ml EGF, 10 g/ml insulin, 1 ng/ml 
cholera toxin, 100 g/ml hydrocortisone, 50 U/ml penicillin and 50 g/ml streptomycin. To 
generate 10A.B2Mock and 10A.B2Cas cells, we transduced MCF10A.B2 with pBabe retroviral 
empty vector or carrying p130Cas cDNA fused with GFP. 
Three-dimensional morphogenetic assay 
3D morphogenetic assays were conducted as previously described in 
http://muthuswamylab.cshl.edu/ml_protocols.html and in (Debnath et al., 2003; Seton-Rogers et al., 
2004). Phase images were collected by using Zeiss microscopy at 4X  magnitude.   
Immunobloting analysis from 3D cultures 
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3D acini were released from Matrigel:Collagen using BD cell recovery solution (BD Biosciences). 
Protein extracts were obtained by lysing acini with RIPA buffer (50mM Tris-HCl pH 7.4, 150mM 
NaCl; 1% Triton X-100, and protease inhibitors). Total cell lysates were separated by SDS-PAGE, 
transferred to nitrocellulose, and immunoblotted overnight with primary antibodies at 4
°
C. Blots 
were incubated with mouse or rabbit horseradish-peroxidase conjugated secondary antibodies for 1 
hour at room temperature. ECL (Euroclone) was used to detect chemoluminescent signals. Protein 
band intensities were determined using the Image J software developed by the NIH. 
Immunofluorescence analysis of 3D acinar structures 
Immunostaining of 3D cultured MCF10.B2 cells was performed as described in  
http://muthuswamylab.cshl.edu/protocols/IF%20protocol.pdf . Images were taken at HCX PL 
APO CS 63X 1.4 OIL Leica TCS-SP5 II confocal microscope and analyzed with LASAF 
software. 
Rac pull-down assay 
Rac1 pull-down assay was performed as described in (Di Stefano et al., 2007). Briefly, glutathione-
coupled Sepharose 4B beads bound to recombinant GST–PAK CRIB domain fusion proteins were 
incubated with cell extracts at 4°C for 45 min, eluted in Laemmli buffer and analysed for the 
presence of Rac1 by Western blot. 
In silico analysis  
The NKI dataset for early stage breast cancer containing 295 breast cancer specimens, analysed on a 
25,000 spot oligonucleotide array as described previously, was used (van de Vijver et al., 2002). 
Only the 102 patients positive for ErbB2 expression (expression above the mean) were considered.  
The difference in ErbB2 expression between patients with high levels of p130Cas and with low 
levels of p130Cas (with respect to the mean expression level across the samples) was determined 
with a two-sided Mann-Whitney U test. 
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Distant metastasis-free survival times was defined as the time to the first event. Overall survival 
times were based on death from any cause. Patients were censored at last follow up. Kaplan-Meier 
survival curves were compared using a log-rank test (R survival package). 
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Results 
In human breast tumours p130Cas and ErbB2 co-expression correlates with metastasis and 
poor prognosis  
Our previous data indicate that p130Cas is involved in ErbB2 tumorigenesis (Cabodi et al., 2006) 
and is required for lung colonisation of ErbB2-transformed cells (Cabodi et al., 2010). The clinical 
relevance of these findings is supported by the in silico analysis that we performed using publicly 
available microarray data from the Netherlands Cancer Institute of 295 early stage breast cancer 
biopsies (van de Vijver et al., 2002). On this set of data we evaluated the expression of p130Cas in 
patients that were positive for ErbB2 (102 out of 295). Interestingly, as shown in the boxplot in 
Figure 1A, the expression of ErbB2 is significantly higher in patients with high levels of p130Cas 
(p130Cas/BCAR1
+
) compared to patients with low levels of p130Cas (p130Cas/BCAR1
-
) 
(P=0.0010 from Mann-Whitney U test) (Figure 1A). Moreover, as visualized with Kaplan-Meier 
plots, patients with breast cancers with concomitant elevated expression of p130Cas and ErbB2 
have a shorter overall survival (P = 0.012, Figure 1B) and, interestingly, a higher risk of developing 
distant site metastasis (P = 0.0445, Figure 1C) compared to patients with low levels of p130Cas. 
Thus, ErbB2 and p130Cas co-expression in this cohort of breast cancer patients significantly 
correlates with metastasis and poor prognosis, supporting the relevance of p130Cas and ErbB2 
cooperation in promoting breast cancer progression. 
 
p130Cas over-expression and ErbB2 activation promote 10A.B2 acini invasion by enhancing 
Erk1/2 MAPK and PI3K/Akt signalling pathways 
To investigate the mechanisms through which high levels of p130Cas and ErbB2 lead to cell 
invasion, we used the MCF10A.B2 grown in 3D (Muthuswamy et al., 2001). MCF-10A.B2 
(10A.B2Mock) cells grown in a 3D matrix composed by Matrigel and collagen I (1:1) form 
polarized, quiescent acini-like spheroids, that upon activation of ErbB2 by treatment with the 
synthetic ligand AP1510, undergo re-initiation of proliferation and disruption of apical polarity, 
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without invading the surrounding matrix (Muthuswamy et al., 2001). In contrast, 10A.B2Cas cells 
that express exogenous p130Cas fused to GFP give rise to multiacinar structures, that upon 
stimulation with AP1510 acquire invasive protrusions (Figure 2B). Migration and invasion of 
mammary epithelial cells transformed by ErbB2 have been ascribed to activation of several 
signalling pathways, including the Extracellular regulated kinase Erk1/2 MAPK and PI3K/Akt 
(Ignatoski et al., 2000; Spencer et al., 2000). Hence, we analysed the activation of these signalling 
pathways in our experimental model. 10A.B2Mock and 10A.B2Cas derived acini were treated 
either with vehicle or with AP1510 and protein extracts from 3D cultures were analysed for levels 
of p130Cas and activation of Akt and Erk1/2 MAPK by using specific antibodies. Interestingly, 
upon ErbB2 activation, phosphorylation of both Akt and Erk1/2 was markedly increased in 
10A.B2Cas compared to 10A.B2Mock acini (Figure 2A). Notably, in this 3D model, p130Cas over-
expression does not enhance the activity of other known ErbB2 induced signalling molecules, such 
as c-Src. c-Src is indeed activated in 10A.B2 cells by treatment with AP1510, but its activation is 
not further enhanced by the over-expression of p130Cas, at least at the time of our analysis (Figure 
S1B). Further, to determine the relevance of the activation of PI3K/Akt and Erk1/2 MAPK 
signalling pathways in conferring the invasive properties to acini over-expressing p130Cas in 
response to ErbB2 activation, 10A.B2Cas acini stimulated with AP1510 were treated with 25 
micromolar PD98059, a MEK-specific inhibitor, or with 10 micromolar LY294002, which blocks 
PI3K activity. As shown in Figure 2B, the treatment with either one inhibitor was sufficient to 
block the formation of invasive protrusions in AP1510-treated 10A.B2Cas cells, indicating that 
PI3K and Erk1/2 cascades are both involved in regulating the invasive behaviour of mammary 
epithelial cells upon concomitant p130Cas over-expression and ErbB2 activation. 
 
ErbB2-induced invasion of 10A.B2Cas acini requires p70S6K activity 
The mammalian target of rapamycin (mTOR) is a 289-kDa serine/threonine kinase that 
belongs to the phosphoinositide 3-kinase (PI3K)-related kinase family and is conserved 
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throughout evolution (Ma et al., 2009; Laplante et al., 2009). mTOR signalling pathway 
integrates and responds to both extracellular and intracellular cues and serves as a central 
regulator of cell metabolism, growth, proliferation and survival. One of the main downstream 
target of mTOR is the p70S6 kinase (p70S6K), involved in the physiological control of protein 
synthesis. (Ma et al., 2009; Laplante et al., 2009). 
Increasing evidences indicate that both the PI3K/Akt and the Erk1/2 MAPK signalling can activate 
mTOR/p70S6K pathway (Klos et al., 2006; Lehman and Gomez-Cambronero, 2002; Sekulic et al., 
2000). Deregulation of the 
 
mTOR/p70S6K pathway may play an important role in cancer 
progression 
 
as well as in many other diseases (Hay and Sonenberg, 2004; Holland et al., 2004). 
Activation of p70S6K is a multistep process starting with the priming phosphorylation on residues 
T421 and S424 within the auto-inhibitory domain by kinases such as Erk1/2 MAPKs, followed by 
phosphorylation of T389 by mTOR that is critical for p70S6K activation (Pearson et al., 1995; 
Saitoh et al., 2002; Thomas, 1993). Although ErbB2 has
 
been shown to activate mTOR/p70S6K 
(Klos et al., 2006), the role of mTOR/p70S6K in ErbB2-mediated
 
cancer invasion remains unclear. 
Consequently, to analyze the effect of p130Cas over-expression on ErbB2-dependent activation of 
the p70S6K pathway, 3D cultures of 10A.B2Mock and 10A.B2Cas were treated or untreated with 
AP1510. p70S6K activity was assessed in cell extracts using phosphospecific antibodies directed 
against p70S6K and the ribosomal subunit protein S6 (S6Rp), a known downstream target of 
p70S6K. Our results indicate that upon ErbB2 activation, p70S6K and its substrate S6Rp are more 
phosphorylated in 10A.B2Cas cells than in 10A.B2Mock cells (Figure 3A). Moreover, to evaluate 
whether the enhanced activation of p70S6K is relevant for ErbB2-dependent invasiveness of 
10A.B2Cas acini, we used the pharmacological inhibitor rapamycin, which specifically blocks 
p70S6K by acting on its upstream activator mTOR. Treatment with 20 nanomolar rapamycin was 
indeed sufficient to strongly reduce the phosphorylation of p70S6K on T389 and of its substrate 
S6Rp (Figure 3B) and to severely impair the formation of invasive protrusions in AP1510-treated 
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10A.B2Cas multiacinar structures (Figure 3C), indicating that p70S6K plays a critical role in 
driving ErbB2-induced invasion in p130Cas over-expressing cells. 
 
p130Cas over-expression enhances ErbB2-dependent mTOR/p70S6K activation via Erk1/2 
MAPK. 
To understand the signalling pathways coordinated by p130Cas and ErbB2 resulting in activation of 
mTOR/p70S6K and leading to invasion, we examined the contribution of PI3K/Akt and Erk1/2 
MAPK on p70S6K activation by using specific inhibitors. Specifically, to explore the effect of 
PI3K/Akt on p70S6K activity, 10A.B2Cas cells, left unstimulated or stimulated with AP1510, were 
treated with 10 micromolar LY294002. As shown in Figure 4, the pharmacological inhibition of 
PI3K results in the reduced phosphorylation of Akt on S473 and does not affect Erk1/2 
phosphorylation. In parallel, p70S6K1 and its target S6Rp are still phosphorylated on T389 and 
S235/236, respectively, indicating that PI3K inhibition does not significantly alter p70S6K1 
activation. Instead, the treatment with 25 micromolar of the MEK inhibitor PD98059 reduces 
Erk1/2 MAPK phosphorylation and impairs p70S6K and S6Rp phosphorylation, without affecting 
Akt phosphorylation. Taken together these data indicate that in response to ErbB2 activation, 
p130Cas over-expression enhances the mTOR/p70S6K pathway via Erk1/2 MAPK activation in a 
PI3K/Akt independent manner. 
 
p130Cas-dependent invasion of ErB2 transformed cells requires Rac1 activation via PI3K. 
It is known that p130Cas promotes actin remodelling by a conserved pathway involving the 
activation of the small GTPase Rac1 (Defilippi et al., 2006; Tikhmyanova et al., 2009). Notably, in 
this work, Rac1 activity was measured in 3D culture conditions by pull down assay from extracts of 
AP1510-stimulated 10A.B2Mock or 10A.B2Cas acini. The concomitant over-expression of 
p130Cas and ErbB2 activation lead to enhanced Rac1 activity compared to 10A.B2Mock (Figure 
5A). Interestingly, inhibition of PI3K with LY294002 prevents the increase in Rac1 activity in 
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response to AP1510 in 10A.B2Cas acini, indicating that p130Cas over-expression coupled to ErbB2 
activation enhances Rac1 activity through the PI3K/Akt pathway (Figure 5A). 
Finally, we examined the involvement of Rac1 in 3D ErbB2-mediated invasion of 10A.B2Cas acini 
by using 80 micromolar NSC23766, a specific Rac1 inhibitor. As shown in Figure 5B, the 
inhibition of Rac1 in AP1510-stimulated 10A.B2Cas abolished the formation of invasive 
protrusions into the surrounding matrix. Importantly, the inhibition of Rac1 does not affect 
upstream pathways as demonstrated by the phosphorylation of Akt, Erk1/2 or S6Rp (Figure 5C). In 
conclusion, our results demonstrate that in ErbB2 transformed 10A.B2Cas cells, the increased 
activity of Rac1 is dependent on PI3K activity and is required for the invasive behaviour of these 
cells.  
Invasive p130Cas over-expressing 10A.B2 cells with activated ErbB2 form 3D matrix 
adhesions. 
The interactions of cells with extracellular matrix (ECM) mediated by integrin receptors are 
required for many cellular processes including cell migration and invasion (Desgrosellier et 
al., 2010). As previously reported by Cukierman et al., 2001, fibroblasts grown in 3D are 
characterized by beta-1 integrin- and fibronectin-based adhesive structures defined as “3D-
matrix-adhesions” that totally differ in composition and function from 2D adhesive 
structures. To investigate the type of adhesive structures of 10A.B2Cas epithelial cells that, 
upon ErbB2 activation, escape from the acinar structures and invade the 3D matrix, we 
performed immunofluorescence experiments. 10A.B2Cas cells grown in 3D and stimulated 
with AP1510, were fixed and stained for beta-1 integrin, F-actin and fibronectin. As shown in 
Figure 6, at the invasive edge of the acini, cells form elongated adhesion fibrillar structures 
characterized by a strong co-localization between beta-1 integrin and fibronectin and 
intracellular bundles of F-actin parallel to extracellular fibronectin fibers. This is the first 
evidence that invading epithelial cells grown in three-dimensional cultures develop specific 3D 
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matrix adhesions, that are different from the adhesive sites observed in 2D (data not shown), 
further underlining the relevance of 3D environment in regulating cell invasion dynamics.   
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Discussion 
In the present work we dissect the signalling pathways through which p130Cas confers invasive 
properties to ErbB-2 activated MCF10A.B2 cells by using a 3D model rather than the traditional 
monolayer culture. We show that the invasive behaviour of p130Cas over-expressing acini upon 
ErbB2 activation relies on the strengthening of Erk1/2 MAPK and PI3K/Akt activation. 
Interestingly, the treatment with pharmacological inhibitors indicates that these signalling pathways 
are both required in order to promote invasion of acinar structures. Moreover, we demonstrate that 
Erk1/2 MAPK and PI3K/Akt signalling confers invasive properties through activation of mTOR/ 
p70S6K and Rac1, as two distinct downstream effectors (Figure 7). Notably, invading epithelial 
cells over-expressing p130Cas and with activated ErbB2 are characterized by 3D matrix 
adhesions that have a distinct architecture compared to 2D adhesions. 
MCF10A.B2 cells, that stably express a chimeric form of ErbB2, give rise to 3D multiacinar 
structures upon ErbB2 activation with a synthetic ligand. These multiacinar acini do not progress 
into an invasive phenotype (Muthuswamy et al., 2001). We showed that ErbB2-activated 
MCF10A.B2 cells acquire the ability to invade in 3D as the result of p130Cas over-expression, 
indicating that high levels of p130Cas are sufficient to drive invasiveness of ErbB2-positive 
mammary epithelial cells (Cabodi et al., 2010). However, the molecular events responsible for 
p130Cas-dependent invasiveness of ErbB2 transformed cells are not fully defined.  
In monolayer cell cultures, the activation of ErbB2 receptors has been reported to induce signalling 
events, including sustained
 
activation of c-Src, Erk1/2 MAPK and PI3K/Akt pathways that have 
been mainly related to cancer cell growth and survival (Graus-Porta et al., 1995; Hu et al., 1992; 
Karunagaran et al., 1996; Marcotte et al., 2009) as well as to cancer cell invasion (Ignatoski et al., 
2000; Spencer et al., 2000). The intriguing and novel finding of the present work is that in a three 
dimensional model of mammary epithelial cells that upon ErbB2 activation closely mimics the in 
vivo mammary gland transformation, p130Cas over-expression strongly enhances Erk1/2 MAPK, 
PI3K/Akt, mTOR/p70S6K and Rac1 activation compared to control cells. All these signalling 
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pathways are involved in mediating invasion of the mammary acini as demonstrated by the loss of 
invasive protrusions after the treatment with pharmacological inhibitors selective for each signalling 
pathway. It is worth noting that p130Cas over-expression by itself is not sufficient to enhance the 
levels of activation of Erk1/2 MAPK, PI3K/Akt, mTOR/p70S6K and Rac1 and to drive invasion, 
that indeed occurs only in presence of the additive activation of ErbB2. This suggests that
 
the 
magnitude and stability of the signalling output in presence of p130Cas is
 
not above the threshold 
necessary to initiate
 
cell invasion, that is reached only in presence of ErbB2 stimulus. Interestingly, 
phosphorylation of c-Src, the major kinase known to phosphorylate p130Cas and a crucial 
transducer in ErbB2 signalling, is not enhanced by p130Cas over-expression in ErbB2 
transformed acini (Figure S1B). In addition, c-Src kinase activity appears to be dispensable 
for driving invasion in 3D, as the treatment of mammary acini with the c-Src inhibitor 
SU6656 does not block cell invasion (Figure S1A). Consistently, Akt and Erk1/2 activities 
were not affected by the treatment with SU6656 (Figure S1B). Therefore, we can speculate 
that ErbB2-dependent c-Src activation is crucial for mediating transformation (Marcotte et 
al., 2009, Cabodi et a., 2010) but dispensable for eliciting cell invasion in 3D.  
In this work, we identify the mTOR/p70S6K pathway, as a novel effector signalling of p130Cas-
dependent invasion of ErbB2 transformed cells. Although it has been reported that both Erk1/2 
MAPK and PI3K/Akt signalling pathways can lead to mTOR/p70S6K activation (Inoki et al., 2002; 
Kelleher et al., 2004; Lehman and Gomez-Cambronero, 2002; Sekulic et al., 2000), our results 
show that in a three-dimensional model the preferential pathway that induce mTOR/p70S6K 
activation depends on ErbB2/p130Cas/Erk1/2 MAPK cascade. This is supported by the fact that the 
treatment with MEK inhibitor markedly reduces p70S6K activation. In contrast, PI3K inhibition 
does not significantly affect Erk1/2 MAPK phosphorylation or p70S6K activation. Thus, p130Cas 
over-expression might preferentially conveys ErbB2 signalling to p70S6K through enhanced Erk1/2 
MAPK activity that overcomes the PI3K/Akt pathway in the regulation of mTOR/p70S6K cascade. 
The fact that ErbB2 dependent activation of Akt in presence of over-expression of p130Cas is not 
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involved in mTOR/p70S6K phosphorylation requires further investigation. Therefore, p130Cas 
over-expression further enhances the ErbB2-dependent activation of Erk1/2 MAPK thus promoting 
phosphorylation and activation of its downstream target mTOR/p70s6K that is required for cell 
invasion. Indeed, treatment with rapamycin, a selective inhibitor of mTOR, is sufficient to inhibit 
cell invasion.  
Notably, it has been assessed that in human breast cancer, ErbB2 over-expression significantly 
correlates with p70S6K phosphorylation and this correlation was reported to be crucial for inducing 
angiogenesis and metastasis formation, underlining the clinical relevance of the activation of the 
mTOR/p70S6K in ErbB2 positive breast carcinoma (Klos et al., 2006).  
In the metastatic process of cancer invasion, the degradation of the extracellular matrix is one of the 
most critical step (Deryugina and Quigley, 2006; Yu et al., 1997). It has been reported that p70S6K 
promotes cell migration and invasion of an ovarian cancer cell line over-expressing ErbB2 by up-
regulating transcription of Matrix Metalloproteinase-9 (MMP-9) (Zhou and Wong, 2006). 
Interestingly, MMP-9 activity is higher upon concomitant activation of ErbB2 and p130Cas over-
expression in mammary epithelial cells grown as a monolayer culture (Cabodi et al., 2010). It is 
likely that one of the final targets of the mTOR/p70S6K signalling cascade may be the induction of 
MMP-9 that enables p130Cas over-expressing acini to invade into the extracellular matrix upon 
ErbB2 activation (Figure 7). Consistently, treatment with MMP-9 inhibitor, abrogates the 
formation of invasive protrusions in ErbB2 transformed acinar structures over-expressing p130Cas 
(data not shown).  
In addition, our results identify Rac1 as a downstream effector of the PI3K/Akt pathway that is 
required for invasion of mammary epithelial acini. We have demonstrated that the concomitant 
over-expression of p130Cas and activation of ErbB2 drive Rac1 activity in 3D conditions. 
Interestingly, treatment with the PI3K inhibitor was sufficient to decrease Rac1 activation to control 
levels. Since we have shown that the PI3K inhibition does not affect the Erk1/2 MAPK pathway, it 
is likely that Erk1/2 MAPK are not involved in the enhanced activity of Rac1. In addition, we show 
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that Rac1 is required for invasion, as demonstrated by the absence of invasive protrusions in 
response of Rac1 inhibitor. It is well documented that p130Cas plays a crucial role in regulating 
actin cytoskeleton remodelling by controlling Rac1 activity (Defilippi et al., 2006; Grimsley et al., 
2004; Hsia et al., 2003). In addition, it has been reported that p130Cas can associate with the p85 
subunit of PI3K in transformed cells (Li et al., 2000; Riggins et al., 2003). Therefore, we can 
speculate that in ErbB2 transformed mammary epithelial cells, high levels of p130Cas may 
facilitate the recruitment and activation of PI3K by ErbB2, that subsequently promote Rac1 
activation, actin cytoskeleton re-organization, cell motility
 
and invasion (Figure 7). Although it is 
known that the PI3K/Akt/Vav2 pathway can lead to the activation of Rac1 (King et al., 2000; 
Papakonstanti and Stournaras, 2002; Welch et al., 2003), the mechanisms that drive PI3K-
dependent Rac1 activation in p130Cas over-expressing acini upon ErbB2 activation remain to be 
elucidated.  
Overall, it is important to highlight that neither the Erk1/2 MAPK/p70S6K nor the PI3K/Akt/Rac1 
pathway is sufficient by itself to elicit cell invasion. Indeed, the inhibition of either one pathway 
blocks the invasive process without affecting the other one. Therefore, the invasive process may be 
the result of the activation of Erk1/2 MAPK/p70S6K and PI3K/Akt/Rac1 pathways that target not 
overlapping effectors involved in distinct functional events. Alternatively, these two signalling 
pathways may converge on the same downstream effector, whose activation occurs only in presence 
of the additive effects of both signalling pathways. 
Importantly, the results of the in silico analysis that we performed by using publicly available 
microarray data from the Netherlands Cancer Institute, (van de Vijver et al., 2002) indicate that 
patients with ErbB2 positive breast cancers and expressing high levels of p130Cas have a higher 
risk of developing metastasis and a shorter overall survival compared to patients with ErbB2 
positive breast cancers for but with lower levels of p130Cas expression. These data suggest that 
expression of p130Cas might serve as indicator of ErbB2 breast cancer progression.  
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In summary, our data emphasize the crucial role of the concomitant over-expression of p130Cas 
and ErbB2 activation in promoting cell invasion. Our data suggest that high levels of p130Cas 
expression function as a molecular switch that by amplifying signals from active ErbB2 and 
intracellular cues promotes the progression from the proliferative to the invasive behaviour, 
pointing out a possible role for p130Cas as a predictive marker for ErbB2 breast cancer progression. 
Most importantly, as p130Cas controls several ErbB2 activated signalling pathways, its targeting is 
likely to be effective for the treatment of ErbB2 over-expressing and invasive breast tumours.  
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Figure legends 
Figure 1: In silico analysis of ErbB2 positive human breast cancer 
A) Higher levels of expression of ErbB2 are detected in patients with high levels of p130Cas 
(p130Cas/BCAR1
+
) compared to patients with low levels of p130Cas (p130Cas/BCAR1
-
) 
(**p<0.001 from Mann-Whithney U test) as shown in the boxplot.  
(B and C) Patients with both high levels of ErbB2 and p130Cas had a significant reduced survival 
(B; p=0.012 ) and increased risk of developing metastasis (C; p=0.045) compared to patients with 
both low levels of ErbB2 and p130Cas as shown by Kaplan-Meier curves. 
 
Figure 2: Erk1/2 MAPK and PI3K/Akt pathways are required for p130Cas and ErbB2-
dependent invasion of MCF10A.B2 cells grown in 3D. 
(A) 10A.B2Mock and 10A.B2Cas cells were plated on a matrix generated by mixing Matrigel and 
collagen I in a 1:1 ratio and stimulated with vehicle or 1 micromolar AP1510 on day 12, 15 and 18. 
On day 19, acinar structures were recovered and lysed. Total cell extracts were analyzed by 
immunoblot and probed with antibodies to p130Cas, pAkt S473, Akt, pErk1/2 and Erk1/2. Right: 
Quantification analysis of three independent experiments. Statistical analysis was performed by 
Student’s t test (*p<0.05, **p<0.01). 
(B) Representative phase images of day-19 acinar structures formed by 10A.B2Mock (upper 
panels), 10A.B2Cas (middle panels) cells un-stimulated or stimulated with AP1510 and 10A.B2Cas 
cells stimulated with AP1510 and treated with PD98059 (25 micromolar) or LY294002 (10 
micromolar) (lower panels). Scale bars, 100 m. 
 
Figure 3: p130Cas/ErbB2 dependent invasion requires mTOR/p70S6K activity. 
(A) 10A.B2Mock and 10A.B2Cas cells were cultured as described in Fig. 2A. Total cell extracts 
were analyzed by immunoblot and probed with antibodies to phospho-p70S6K (pS6K T421/S424 
and T389), p70S6K (S6K), phospho-S6Rp (pS6Rp S235/236) and S6Rp. Right: Quantification 
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analysis of three independent experiments. Statistical analysis was performed by Student’s t test 
(*p<0.05, **p<0.01). 
(B) 10A.B2Cas acini were cultured as in (A) and stimulated with AP1510 (1 micromolar) in the 
presence of rapamycin (20 nanomolar). Total cell extracts were analyzed by immunoblot and 
probed with antibodies to phospho-p70S6K (pS6K T389), p70S6K (S6K), phospho-S6Rp (pS6Rp 
S235/236) and S6Rp.  
(C) Representative phase images of day-19 acinar structures formed by un-stimulated 10A.B2Mock 
and 10A.B2Cas acinar structures (left panels), 10A.B2Mock and 10A.B2Cas stimulated acini with 
AP1510 (middle panels) and 10A.B2Cas cells stimulated with AP1510 and treated with rapamycin 
(20 nanomolar) (right panel). Scale bars, 100 m. 
Figure 4: p130Cas over-expression enhances ErbB2-dependent mTor activation via Erk1/2 
MAPK. 
(A) Western blot analysis was performed on cell extracts from un-stimulated or AP1510-stimulated 
10A.B2Mock and 10A.B2Cas acini and from 10A.B2Cas acini stimulated with AP1510 and treated 
with PD98059 (25 micromolar) or LY294002 (10 micromolar). Cell extracts were probed with 
antibodies to pAkt S473, Akt, pErk1/2, Erk1/2, phospho-p70S6K (pS6K T389), p70S6K (S6K), 
phospho-S6Rp (pS6Rp S235/236) and S6Rp. 
(B) Quantification analysis of three independent experiments. Statistical analysis was 
performed by Student’s t test (*p<0.05, **p<0.01). 
Figure 5: Rac1 inhibition is sufficient to abrogate invasion of ErbB2 transformed 10A.B2Cas 
acini. 
(A) 10A.B2Mock and 10A.B2Cas acini were stimulated with AP1510 on day 12 and 15, in 
presence or absence of LY294002 (10 micromolar), and lysed on day 16. Active Rac1 was pulled 
down from total protein extracts using the CRIB domain of PAK and detected by Western blot with 
an anti-Rac1 mAb (upper panel). Amount of total Rac1 in protein extracts is shown in the lower 
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panel. Right panel: Quantification analysis of three independent experiments. Statistical analysis 
was performed by Student’s t test (*p<0.05). 
(B) Representative phase images of day-19 acinar structures formed by unstimulated 10A.B2Mock 
and 10A.B2Cas acinar structures (left panels), 10A.B2Mock and 10A.B2Cas stimulated acini with 
AP1510 (middle panels) and 10A.B2Cas cells stimulated with AP1510 and treated with NSC23766 
(80 micromolar) (right panel). Scale bars, 100 m. 
(C) 10A.B2Mock and 10A.B2Cas cells were cultivated as described in Fig. 2A. 10A.B2Cas acini 
were stimulated with AP1510 in the presence of NSC23766 (80 micromolar). Total cell extracts 
were probed with antibodies to pAkt S473, Akt, pErk1/2, Erk1/2, phospho-S6Rp (pS6Rp S235/236) 
and S6Rp.  
Figure 6: ErbB2 transfomed 10A.B2Cas invasive cells are characterized by “3D matrix 
adhesions”.   
Representative confocal images of AP1510-stimulated 10A.B2Cas acini fixed and stained for 
F-actin (purple, panel a), beta-1 integrin (red, panel b) and fibronectin (green, panel c). 
Merged images are shown in panel d. Magnifications of the insets are shown in panels e, f, g 
and h, respectively. White arrows in panel h indicate co-localization between beta-1 integrin 
and fibronectin. Scale bars represent 25 μm. Images were taken at HCX PL APO CS 63X 1.4 
OIL Leica TCS-SP5 II confocal microscope and analyzed with LASAF software. 
Figure 7: Signaling pathways leading to 3D invasion of ErbB2 transformed 10A.B2Cas acini. 
In ErbB2 transformed 10A.B2 mammary epithelial cells, the over-expression of p130Cas 
triggers invasion by acting on both the PI3K/Akt and Erk1/2 pathways. mTOR/p70S6K 
signalling pathways is preferentially activated by the ErbB2/p130Cas/Erk1/2 MAPK cascade. 
Treatment with MEK inhibitor abrogates cell invasion by affecting mTOR/p70S6K pathway. 
On the other side, PI3K inhibition blocks cell invasion but does not significantly affect Erk1/2 
MAPK phosphorylation or p70S6K activation. In parallel, the ErbB2/p130Cas/PI3K/Akt 
cascade triggers Rac1 activation. Both signalling pathways are required for epithelial cell 
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invasion suggesting that they cooperate in the regulation of different processes that ultimately 
lead to cell invasion.  
 
